We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current TCRX market cap is 227.36M. The company's latest EPS is USD -1.6717 and P/E is -2.55.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 3.15M | 3.89M | 7.21M | 566k | 536k |
Operating Income | -24.61M | -24.75M | -21.36M | -31.37M | -34.11M |
Net Income | -24.05M | -23M | -19.61M | -30.14M | -31.66M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 1.09M | 10.14M | 13.54M | 21.05M |
Operating Income | -14.21M | -26.23M | -48.64M | -66.64M | -93.46M |
Net Income | -13.66M | -26.23M | -48.63M | -66.22M | -89.22M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 316.92M | 291.38M | 272.15M | 240.83M | 374.87M |
Total Liabilities | 126.32M | 122.42M | 121.28M | 117.87M | 119.65M |
Total Equity | 190.61M | 168.96M | 150.87M | 122.97M | 255.22M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 49.38M | 49.74M | 188.11M | 199.09M | 272.15M |
Total Liabilities | 6.84M | 32.52M | 27.33M | 99.66M | 121.28M |
Total Equity | -17.14M | -42.46M | 160.78M | 99.43M | 150.87M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -45.61M | -37.59M | -61.36M | -29.27M | -55.49M |
Investing | -1.26M | -62.67M | -60.76M | 36.16M | 2.45M |
Financing | 135.68M | 135.42M | 135.44M | 258k | 161.85M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -12.52M | -3.02M | -48.68M | -66.5M | -61.36M |
Investing | -1.25M | -4.24M | -9.94M | -4.23M | -60.76M |
Financing | 34.81M | 288k | 189.67M | 29.36M | 135.44M |
Market Cap | 227.36M |
Price to Earnings Ratio | -2.55 |
Price to Sales Ratio | 10.8 |
Price to Cash Ratio | 1.7 |
Price to Book Ratio | 1.51 |
Dividend Yield | - |
Shares Outstanding | 53.37M |
Average Volume (1 week) | 202.4k |
Average Volume (1 Month) | 270.25k |
52 Week Change | 3.15% |
52 Week High | 9.69 |
52 Week Low | 3.73 |
Spread (Intraday) | 1.72 (28.96%) |
Company Name | TScan Therapeutics Inc |
Address |
3500 s dupont hwy dover, delaware 19901 |
Website | https://www.tscan.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions